Focused Alpha LLC Purchases 992 Shares of United Therapeutics Corporation $UTHR

Focused Alpha LLC acquired a new stake in United Therapeutics Corporation (NASDAQ:UTHR) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 992 shares of the biotechnology company’s stock, valued at approximately $538,000.

Several other hedge funds have also modified their holdings of UTHR. Toth Financial Advisory Corp increased its stake in shares of United Therapeutics by 2,400.0% in the 2nd quarter. Toth Financial Advisory Corp now owns 50 shares of the biotechnology company’s stock valued at $27,000 after purchasing an additional 48 shares in the last quarter. Fiduciary Financial Advisors purchased a new position in United Therapeutics during the second quarter worth approximately $30,000. Caitlin John LLC purchased a new position in United Therapeutics during the second quarter worth approximately $37,000. International Assets Investment Management LLC grew its holdings in United Therapeutics by 426.7% in the first quarter. International Assets Investment Management LLC now owns 79 shares of the biotechnology company’s stock valued at $45,000 after purchasing an additional 64 shares during the period. Finally, Keating Financial Advisory Services Inc. acquired a new stake in United Therapeutics in the second quarter valued at approximately $81,000. 94.08% of the stock is owned by hedge funds and other institutional investors.

United Therapeutics Price Performance

Shares of NASDAQ:UTHR opened at $543.15 on Tuesday. The business’s 50 day moving average price is $513.91 and its 200-day moving average price is $539.71. The firm has a market capitalization of $23.30 billion, a PE ratio of 19.43, a P/E/G ratio of 3.81 and a beta of 0.49. United Therapeutics Corporation has a 1 year low of $409.07 and a 1 year high of $609.35.

United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.86 by $0.41. The business had revenue of $783.30 million during the quarter, compared to analyst estimates of $804.65 million. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. The company’s revenue for the quarter was down 1.9% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $6.41 earnings per share. As a group, analysts expect that United Therapeutics Corporation will post 26.40 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the company. Leerink Partners upped their target price on United Therapeutics from $685.00 to $725.00 and gave the stock an “outperform” rating in a research note on Monday. JPMorgan Chase & Co. lifted their price target on shares of United Therapeutics from $685.00 to $687.00 and gave the company an “overweight” rating in a research note on Thursday, July 23rd. Morgan Stanley boosted their price target on shares of United Therapeutics from $515.00 to $566.00 and gave the stock an “equal weight” rating in a report on Wednesday, October 7th. Cantor Fitzgerald restated an “overweight” rating on shares of United Therapeutics in a research report on Thursday, October 1st. Finally, Royal Bank Of Canada increased their price objective on shares of United Therapeutics from $677.00 to $708.00 and gave the company an “outperform” rating in a report on Thursday, October 8th. Twelve equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $650.00.

Insiders Place Their Bets

In related news, CEO Martine Rothblatt sold 9,500 shares of the company’s stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $516.06, for a total transaction of $4,902,570.00. Following the completion of the sale, the chief executive officer owned 324,443 shares of the company’s stock, valued at approximately $167,432,054.58. This represents a 2.84% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have sold 392,028 shares of company stock worth $202,907,986 in the last quarter. Insiders own 8.60% of the company’s stock.

United Therapeutics Profile

United Therapeutics Corporation is a biotechnology company focused on developing and commercializing therapies for patients with life-threatening conditions, particularly pulmonary arterial hypertension (PAH). The company’s portfolio includes Tyvaso and Tyvaso DPI, inhaled formulations of treprostinil; Remodulin, an injectable treprostinil product; and Orenitram, an oral treprostinil therapy. These treatments are designed to improve exercise ability and delay disease progression in people with PAH.

The company also markets Unituxin, an antibody therapy used as part of treatment for high-risk neuroblastoma, a type of childhood cancer.